CheckMate 743 Five-Year Update: Nivolumab Plus Ipilimumab Maintains Long-Term Survival Benefit in Unresectable Pleural Mesothelioma
Bishal Gyawali: ASCO Guidelines Shaped Me - Now I Help Shape What’s Next
Biopharma Faces Revenue Squeeze as 275 Billion Dollars at Risks
Scott Kopetz: FDA Grants Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line mCRC
Margaret Foti: Grateful to Congress for Supporting NIH and NCI
Maite Bourlon: Happy to be ASCO Voice at This ASCO GU 2026
Deepti Sharma: A Global Collaborative Forum on Cancer Care
Susanna Fletcher Greer: Stories Like This Beautiful One Stay With Me
